https://rumahjurnal.or.id/index.php/jim/issue/feedJIM - Journal International Multidisciplinary2024-07-31T00:00:00+00:00Mitra Unik M.Komjurnaljim@gmail.comOpen Journal Systems<p><strong>JIM - Journa</strong>l <strong>International</strong> <strong>Multidisciplinary</strong> is published 2 (two) times a year in January and July by the Rahmatan Fiddunya Wal Akhirah Foundation in assisting academics, researchers and practitioners to disseminate their research results. The purpose of the JIM Journal is as a means to publish papers / articles in multidisciplinary science.</p>https://rumahjurnal.or.id/index.php/jim/article/view/889Innovative Utilization of Orange Peel Waste through Modified Citrus Pectin (MCP) as a Preventive Agent Against Atherosclerosis Progression via Galectin-3 (Gal-3) Inhibition: A Comprehensive Literature Review on In Vitro and In Vivo Study Designs2024-07-16T07:24:28+00:00Fauzan Syarif Nursyafi2010347003_fauzan@student.unand.ac.idLamirza Rasyid Mikzy Febrian2310341003_lamirza@student.unand.ac.idRivaldi Dwi Putra2310342010_rivaldi@student.unand.ac.idHagil Alghufron Renato2310342012_hagil@student.unand.ac.idDio Kurniawan2010342001_dio@student.unand.ac.id<p>Atherosclerosis is an arterial disease often associated with lipids and other metabolic alterations. Various factors are involved in developing atherosclerosis, including Galectin-3 (Gal-3). Pre-clinical studies have shown that Modified Citrus Pectin (MCP), a modified polysaccharide from citrus peels, has the potential of inhibiting Gal-3 and countering the development of atherosclerosis. Thus, this review aims to analyze the role of MCP on inhibiting and regulating Galectin-3 (Gal-3) as an alternative therapeutic target. We examined valid pre-clinical experimental study designs taken from the databases Science Direct, Taylor & Francis, PubMed, and Google Scholar, with publication dates ranging from 2014 to 2024. 15 research articles meet the established inclusion criteria. Our review found that Gal-3 levels rose during atherosclerosis development, triggering proteins that disturbs cardiovascular physiology. Additionally, Gal-3 targeted inhibition using MCP has shown to have therapeutic effects that alleviates hypertrophy and plaque’s size. In essence, MCP emerges as a promising alternative therapy targeting Gal-3 in atherosclerosis progression.</p>2024-07-31T00:00:00+00:00Copyright (c) 2024 JIM - Journal International Multidisciplinary